Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:12/19/2014)... 2014   Hospira, Inc. (NYSE: ... and infusion technologies, today announced that the company will ... on Wednesday, Jan. 14, 2015, in San Francisco.  ... at 10:30 a.m. Pacific time on Wednesday, Jan. 14, ... through a live audiocast accessible via the Investor Relations ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... Aug. 3 Omnicell, Inc ., (Nasdaq: ... system solutions to acute healthcare facilities, today released the new ... The next generation of packaging technology supports bar code medication ... accuracy. Integrated with the latest WorkflowRx software, version 7.0, this ...
... BEIJING , Aug. 3 ... LTUS ) ("Lotus" or the "Company"), ... in the People,s Republic of,China (the "PRC"), ... ingredient ("API") and tablets of R-Bambuterol for use in,clinical ...
Cached Medicine Technology:Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency 2Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency 3Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency 4Lotus Completed R-Bambuterol's Pilot Scale Production for Clinical Trials 2Lotus Completed R-Bambuterol's Pilot Scale Production for Clinical Trials 3
(Date:12/19/2014)... (PRWEB) December 20, 2014 The print ... Home and Business subscription of the Toronto Star, with ... readership of 622,169. The digital component is distributed nationally ... network of top news sites and partner outlets. To ... here . , The publication features an exclusive ...
(Date:12/19/2014)... -- The intestinal bacteria that cause inflammatory bowel disease, ... inherited, researchers report. The findings, published recently in ... efforts to prevent the disease and treat the 1.6 ... added. "The intestinal bacteria, or ,gut microbiome, you ... big impact on your health for the rest of ...
(Date:12/19/2014)... Potentially illness-causing E. coli bacteria were found on nearly ... a new study. Researchers checked cilantro, basil and ... in Los Angeles and Orange counties in California, and ... tested, 24 percent were positive for E. coli. One ... Both types of bacteria can cause sometimes serious ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Dense bunches of bacteria called ... a new study finds. The researchers said these ... colon. The presence of these biofilms may represent an ... way to predict a person,s risk for the disease, the ... stones, these biofilms may coat the mucus layer of cells ...
(Date:12/19/2014)... Older adults who have lost all their teeth have faster ... have at least some of their teeth, a new study ... provide an early warning of increased risk of physical and ... However, the findings don,t prove that tooth loss causes the ... 3,100 participants 60 and older. People with no remaining teeth ...
Breaking Medicine News(10 mins):Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2
... of Public Health has awarded CNN anchor and special ... efforts while reporting on the devastating effects of Hurricane ... with the award at a ceremony at the Bloomberg ... O,Brien has shown the world tragedies of human conflict, ...
... by New Legislation , , ... (UBC) Annette Stemhagen, DrPH, FISPE, and Gerald Faich, MD, ... Summit held in Washington, DC, on October 28 and ... Jane Axelrad, Associate Director for Policy, CDER, FDA; Claudia ...
... group of consumers filed a proposed,nationwide class-action lawsuit earlier ... AG (FRA: BAY), alleging the pharmaceutical giant,skirted FDA requirements ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ... that Bayer markets two of its over-the-counter products --,Bayer ...
... Health plans today proposed guaranteed coverage for people with pre-existing ... , , Under the ... market would be required to offer coverage to all applicants ... individuals were required to maintain health insurance. , ...
... How is a Shortage of Primary Care Physicians Affecting the ... the American College of Physicians (ACP) documents the value of ... bibliography based on a literature review of more than 100 ... primary care in providing patients with better outcomes at lower ...
... they can raise long-term health risks, studies say , , ... poor caregiver relationships each increase levels of the stress ... two studies, published in the November/December issue of ... on children in these common situations. , Long-term or ...
Cached Medicine News:Health News:Bloomberg School awards Goodermote Humanitarian Award to Soledad O'Brien 2Health News:United BioSource Scientists, FDA, and Other Industry Leaders Present to Risk Management and Drug Safety Summit 2Health News:United BioSource Scientists, FDA, and Other Industry Leaders Present to Risk Management and Drug Safety Summit 3Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 3Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 2Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 3Health News:Primary care provides patients with better outcomes at lower cost 2Health News:Child-Care Relationships Tied to Kids' Stress Levels 2Health News:Child-Care Relationships Tied to Kids' Stress Levels 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: